ADMA Biologics, Inc. is a specialty immune globulin company that develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. The Company�s targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons. The Company�s product candidate, RI-002, for which it has commenced a pivotal Phase III clinical trial, is intended for the treatment of primary immune deficiency disease (PIDD). RI-002 is an injectable immune globulin derived from human plasma enriched with levels of naturally occurring polyclonal antibodies, including those targeted to respiratory syncytial virus (RSV). RSV is a common virus that ordinarily leads to mild, cold-like symptoms in healthy adults and children. On February 13, 2012, the Company merged into a subsidiary of R&R Acquisition VI, Inc.